ArticleAsian Pacific journal of cancer prevention : APJCP2025
Mismatch Repair Proteins Immunostaining in Lip Squamous Cell Carcinoma: A Role in Lip Carcinogenesis?
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLip squamous cell carcinoma (LSCC) is associated with malignant transformation of actinic cheilitis (AC). Since solar radiation alters the functions of mismatch repair (MMR) complex, we evaluated for their possible role in lip carcinogenesis. MATERIALS AND
methodsSamples of normal lip epithelia (NLE) (n=15), AC (n=30), and LSCC (n=45) were subjected to immunohistochemistry for MutSα (MSH2/MSH6) and MutLα (MLH1/PMS2) to assess the percentage (brown nuclei over all the keratinocytes in NLE and AC or all tumoral cells in LSCC) of nuclear positive cells and MSH2/MSH6 (MutSα-imbalance) and MLH1/PMS2 (MutLα-imbalance) ratios. Clinical-prognostic variables of the primary tumor and histopathological gradation (LSCC and AC) were evaluated. Mann-Whitney, Kruskal-Wallis/Dunn, and Spearman correlation tests were used (p<0.05, SPSS 20.0).
resultsLSCC and AC showed significant increases in MSH2 (p<0.001), MSH6 (p<0.001), MLH1 (p=0.040) percentage of immunostained cells, and MutSα-imbalance (p<0.001). MutSα-imbalance in AC was higher than MutLα-imbalance (p=0.028). In LSCC, T3/T4 tumors showed higher MutSα-imbalance (p=0.028) and MutLα-imbalance (p=0.014). In LSCC with nodal metastasis, the MutLα-imbalance was significantly higher than the MutSα-imbalance (p=0.046). AC with high-risk dysplasia (p=0.024) and LSCC with vascular invasion (p=0.035) showed lower immunostaining for MSH6. Direct correlations between MMR-proteins increased in LSCC.
conclusionsIncreased MMR expression in lip cancer and the imbalance between MutSa and MutLα is associated with the progression and prognosis of LSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.